Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
Oncology Innovation, real-world data, and precision medicine: Pierre ... Ahead of ASCO 2025, Pierre Fabre charts bold progress in NSCLC with targeted therapies, real-world data, and innovative partnerships
Oncology AACR 2025: New modalities and remaining challenges Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges
R&D How Japan is pioneering the future of oncology clinical tria... Discover how Japan is leading the way in oncology clinical trials through the implementation of decentralised clinical trials
Webinars Sponsored Oncology treatment decisions aren’t just based on clinical d... Once widely acknowledged as so special that only scientists and clinical specialists need to apply, oncology has become exponentially more clinically targeted and sophisticated over the las
Oncology Sponsored Unlocking health data to improve oncology outcomes The NHS’ globally unique health data ecosystem has the potential to improve health outcomes.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face